Welcome to GenPrice! Check out our latest updates.

Shopping Cart (0)

Your cart is empty

Add some products to get started!

Bergapten

5-Methoxypsoralen, a naturally occurring linear furocoumarin, has been successfully used in combination with ultraviolet (UV) A irradiation [psoralen plus UV (PUVA) ] to manage psoriasis and vitiligo; inhibit proliferation in the human hepatocellular carcinoma cell line. (In Vitro) :There is decreased N-acetyltransferase (NAT) activity in SC-M1 cells at concentrations of Bergapten (5-Methoxypsoralen, 5-MOP) from 0.05 mM to 25 mM, but no obvious dose-dependent effect is found between these doses (r=0.5687) . In COLO 205 cells, there is decreased NAT activity at low doses of Bergapten (0.05 mM and 0.5 mM) and increased NAT activity at a high dose (50 mM) . Bergapten induces a dosedependent effect in our experimental concentrations on COLO 205 cells (r=0.8912) ; a promotion effect at a higher dose (50 mM) and an inhibition effect at lower doses (0.05-0.5 mM), while the concentrations 5-25 mM has no significant difference compared with the control regimen. Bergapten (5-Methoxypsoralen) exerts inhibitory effects on diabetes-related osteoporosis via the regulation of the PI3K/AKT, JNK/MAPK and NF-κB signaling pathways in osteoprotegerin knockout mice. Bergapten has also been shown to significantly inhibit the production of pro-inflammatory cytokines. Bergapten exhibits the ability to significantly inhibit RANKL-RANK signaling transduction, and to suppress the activation of the PI3K/AKT, JNK/MAPK and NF-κB signaling pathways, thus protecting trabecular structure and decreasing osteoclastogenic differentiation. (In Vivo) :The metabolic activity of NAT of the rat colon is higher than that of the stomach, and Bergapten (5-Methoxypsoralen, 5-MOP) causes a decrease of AF concentration in the stomach at the 24-h time-period. The concentrations of AAF in the stomach and colon are low. Although DMSO (solvent) influenced the metabolism of AAF, compared with the control regimen, Bergapten still causes an increase in the further metabolism of AAF, and a decrease in the concentration of AAF in the stomach at 24 h, and in the colon during the 24- to 72-h time-period.

Product Specifications

CAS Number

484-20-8

Field of Research

Pharmacology & Drug Discovery

Purity

>98% (HPLC)

Solubility

DMSO: 5 mg/mL (23.12 mM)

Smiles

COC1=C2C=CC (=O) OC2=CC2=C1C=CO2

Molecular Formula

C12H8O4

Molecular Weight

216.19

Storage Conditions

Storage temperature: -20°C. Stability: ≥ 2 years

Notes

For research use only.

Available Sizes

Frequently Asked Questions

More Discoveries

Explore Other Products

Browse additional items from our catalog

OSBPL10 Knockout A549 Polyclonal Cells
ARG10459 1 Million

OSBPL10 Knockout A549 Polyclonal Cells

Sign In for Pricing
View Details
Human PLAAT5 Pre-designed siRNA Set B
SI012290B 1 Each

Human PLAAT5 Pre-designed siRNA Set B

Sign In for Pricing
View Details
Mmu-miR-468-5p miRNA Antagomir
CIN1119-01 10 nmol

Mmu-miR-468-5p miRNA Antagomir

Sign In for Pricing
View Details
Mmu-miR-468-5p miRNA Antagomir
CIN1119-02 20 nmol

Mmu-miR-468-5p miRNA Antagomir

Sign In for Pricing
View Details
LENEP Protein Vector (Rat) (pPM-C-HA)
PV277332 500 ng

LENEP Protein Vector (Rat) (pPM-C-HA)

Sign In for Pricing
View Details
CCT4, NT (CCT4, CCTD, SRB, T-complex protein 1 subunit delta, CCT-delta, Stimulator of TAR RNA-binding) (MaxLight 750)
MBS6282672-01 0.1 mL

CCT4, NT (CCT4, CCTD, SRB, T-complex protein 1 subunit delta, CCT-delta, Stimulator of TAR RNA-binding) (MaxLight 750)

Sign In for Pricing
View Details